Latest Conference Articles

“This is the first phase 3 study to show an advantage of a PARP inhibitor over standard of care chemotherapy in breast cancer patients with a BRCA mutation,” said principal OLYMPIAD investigator Mark E. Robson, M.D., Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center.

Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.

Sue Friedman, executive director and founder of FORCE, is a hereditary breast cancer survivor herself and has been concentrating on being the support system for others that she didn’t have when she was going through her battle 20 years ago.

The program XRAYS is a resource to help patients, survivors and their loved ones make sense of the articles on hereditary cancer they see in the mainstream media and via social media platforms.

While genetic testing for cancer has some obvious benefits, it also creates ethical dilemmas in many cases.

PolyBalm was effective in mitigating chemotherapy-related nail damage, according to a recent study presented at ASCO.

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.

An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.

According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.

The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.

According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.

There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.

A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.

Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.

The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.